Clinical trials: AD
Alzheimer's Disease
PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers
The purpose of this study is to investigate the radiotracer [11C] PIB in participants with probably Alzheimer's Disease (AD) and healthy age-matched controls.
- Trial name
- NCT01826110
- Testing
- [11C]PIB
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
MCI, Aging
Cognitive-Motor Training for AD/ADRD Prevention
Alzheimer's disease and related dementias (AD/ADRD) greatly affect memory and daily activities in older adults. Mild Cognitive Impairment (MCI) is an early stage of dementia, affecting about 17% of older adults.
- Trial name
- NCT07160582
- Testing
- Novel CogXergaming Training, Exercise and Education Training Program
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Alzheimer's Disease
Cognitive Rehabilitation in Alzheimer's Disease
This study aims to proof the efficacy of a cognitive rehabilitation program for patients with mild dementia in Alzheimers Disease with respect to activities of daily living.
- Trial name
- NCT02247180
- Testing
- cognitive rehabilitation, standardized cognitive training
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- University of Rostock
Chronic Lymphocytic Leukemia
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
The study is a Phase I, dose-escalating, non-randomized, single institution clinical trial assessing the safety and efficacy of autologous Ad-ISF35-transduced CLL B cells administered as a single intravenous infusion in patients…
- Trial name
- NCT00779883
- Testing
- ISF35
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memgen, LLC
Healthy Volunteers
Pharmacokinetic Study Comparing Nicotine Delivery From E-cigarettes and a Conventional Cigarette in Healthy Subjects
This study will compare nicotine delivery, heart rate, puffing parameters and product satisfaction in healthy subjects either using several different types of electronic cigarettes or smoking a conventional cigarette.
- Trial name
- NCT02474849
- Testing
- Use electronic cigarette or smoke conventional cigarette
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- British American Tobacco (Investments) Limited
Atopic Dermatitis
Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical…
- Trial name
- NCT03703102
- Testing
- KHK4083
- Where
- 58 sites in United States, Canada and 2 more
- Volunteers
- 274 people
- Sponsor
- Kyowa Kirin, Inc.
Alzheimer Disease, Parkinson Disease
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients
This double-blind, randomized, placebo-controlled, investigator-initiated, multi-centre trial aims to establish metabolic improvements in AD and PD subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine…
- Trial name
- NCT04044131
- Testing
- Metabolic Cofactor Supplementation, Sorbitol
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Istanbul Medipol University Hospital
Alzheimer Disease, Primary Progressive Aphasia
Identification of Graphic Markers of Neurocognitive Disorders (MG)
The diagnosis of neurocognitive disorders such as early Alzheimer's disease (AD) or primary progressive aphasia (PPA) is particularly difficult and constantly evolving, often leading to diagnostic erraticity.
- Conditions
- Alzheimer Disease, Primary Progressive Aphasia, Neurocognitive Disorders
- Trial name
- MG (NCT05537688)
- Testing
- Identification of Graphic Markers
- Where
- Canada
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
Financial Hardship, Alzheimer's Disease (AD)
Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia
Alzheimer's Disease and related dementias (AD/ADRD) are common and debilitating conditions. Financial hardship, a multidimensional construct of financial strain, financial stress and asset depletion, is common in AD/ADRD due to…
- Conditions
- Financial Hardship, Alzheimer's Disease (AD), Alzheimer's Disease and Related Dementia (ADRD)
- Trial name
- AD/ADRD (NCT06922188)
- Where
- United States
- Volunteers
- 2,460 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Alzheimer's Disease
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
- Trial name
- CREAD (NCT02670083)
- Testing
- Crenezumab
- Where
- 196 sites in United States, Australia and 28 more
- Volunteers
- 813 people
- Sponsor
- Hoffmann-La Roche
Atopic Dermatitis (AD)
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT07298395
- Testing
- ENV-294
- Where
- 32 sites in United States
- Volunteers
- 105 people
- Sponsor
- Enveda Therapeutics
Atopic Dermatitis (AD)
Efficacy of Jelly Fig (Ficus Awkeotsang Makino) Extract for Atopic Dermatitis
The study is designed to evaluate the efficacy and safety of a topical formulation containing Ficus awkeotsang Makino extract (FAE), derived from jelly fig, in participants with mild to moderate atopic dermatitis.
- Trial name
- NCT07113366
- Testing
- FAE cream
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Alzheimer's Disease
Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the tolerability and safety of repeated subcutaneous injection of a single dose of AFFITOPE AD02 in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00633841
- Testing
- AFFITOPE AD02
- Where
- Austria
- Volunteers
- 24 people
- Sponsor
- Affiris AG
Alzheimer's Disease
Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)
Alzheimer Disease (AD) is a progressive brain disease generally known as senile dementia. Our proposed study will establish safety and pharmacokinetics of Meganatural-AZ GSPE in AD subjects.
- Trial name
- NCT02033941
- Testing
- Meganatural-Az Grapeseed Extract
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hillel Grossman
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
[18F]APN-1607 PET in Subjects With AD Compared to HC
The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MCI, subjects with AD dementia, and healthy subjects.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
- Trial name
- NCT05542953
- Testing
- [18F]APN-1607
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics
Atopic Dermatitis
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
This is a multicentre, prospective, non-interventional study that aims to describe the treatment patterns of in Atopic dermatitis (AD) patients aged 6 months to 11 years old in Spain: patients' characteristics, disease…
- Trial name
- PROADAP (NCT06415175)
- Testing
- Dupilumab
- Where
- 15 sites in Spain
- Volunteers
- 143 people
- Sponsor
- Sanofi
Taste Sensitivity, Umami Taste Perception
Umami Taste Intensity and Meal Intake
Sweet and salty tastes can influence food intake. Increased intensity of these tastes has been shown to decrease food intake and increase satiation compared to the less intense taste, independent of palatability.
- Conditions
- Taste Sensitivity, Umami Taste Perception, Food Intake Regulation, Hedonic Function
- Trial name
- OptUmami (NCT07421466)
- Testing
- Hedonic mapping, Ad libitum risotto test meal
- Where
- Netherlands
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Wageningen University
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Alzheimer Dementia (AD), Caregivers
MUSic Listening Impact on QUality of Life, Brain and Burnout of ALzheimer' Patients Informal Caregivers
Although life expectancy is increasing, the risk of dependence and/or loss of autonomy is increasing too with ageing. Alzheimer's disease affects many people and this kind of disease is constantly growing.
- Trial name
- MUSIQUAL+ (NCT07159542)
- Testing
- listening intervention, Neuropsychology assessment, brain imaging examination
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Alzheimer's Disease, Primary Progressive Non-fluent Aphasia
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
The purpose of this study is to determine safety, tolerability, and pharmacokinetics/dynamics of a ketogenic dietary supplement containing medium chain triglycerides (MCTs) in patients with Alzheimer disease (AD).
- Conditions
- Alzheimer's Disease, Primary Progressive Non-fluent Aphasia, Frontotemporal Dementia (FTD)
- Trial name
- MINT-01 (NCT02912936)
- Testing
- Ketogenic medium chain triglyceride drink (MCT drink)
- Where
- Canada
- Volunteers
- 43 people
- Sponsor
- University of British Columbia